
Agile Therapeutics AGRX
Quartalsbericht 2024-Q2
hinzugefügt 23.05.2026
Agile Therapeutics Kurzfristige Verbindlichkeiten 2011-2026 | AGRX
Kurzfristige Verbindlichkeiten Jährlich Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.8 M | 13.4 M | 29.3 M | 7.35 M | 3.8 M | 2.22 M | 14.3 M | 11 M | 7.78 M | 8.99 M | 6.84 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 29.3 M | 2.22 M | 11.4 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
10.4 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
36.7 M | $ 5.6 | - | $ 83.2 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
7.71 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
48.2 M | $ 2.63 | -1.87 % | $ 1.01 B | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
96.3 M | $ 38.93 | 3.43 % | $ 1.43 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
Organogenesis Holdings
ORGO
|
100 M | $ 2.41 | 2.99 % | $ 305 M | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 22.74 | -1.09 % | $ 1.05 B | ||
|
Canopy Growth Corporation
CGC
|
158 M | $ 0.98 | -1.71 % | $ 105 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 1.11 | 1.83 % | $ 1.38 M | ||
|
Solid Biosciences
SLDB
|
33.5 M | $ 7.36 | 3.08 % | $ 644 M | ||
|
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
Tilray
TLRY
|
433 M | $ 5.01 | 0.6 % | $ 3.1 B | ||
|
Evolus
EOLS
|
75.3 M | $ 6.75 | 0.3 % | $ 435 M | ||
|
Emergent BioSolutions
EBS
|
132 M | $ 8.29 | -0.36 % | $ 444 M | ||
|
Veru
VERU
|
7.79 M | $ 3.13 | 4.33 % | $ 45.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
3.19 M | $ 0.67 | -2.33 % | $ 2.7 M | ||
|
Assertio Holdings
ASRT
|
128 M | $ 23.5 | 0.09 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
53.1 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
4.18 B | $ 4.99 | -1.38 % | $ 1.85 B | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
6.43 M | $ 6.37 | -4.21 % | $ 251 M | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
163 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
5.73 M | $ 4.09 | -3.31 % | $ 204 M | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
7.09 B | $ 16.32 | -0.97 % | $ 19 B | ||
|
Zomedica Corp.
ZOM
|
9.45 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
9.58 M | $ 0.64 | 2.74 % | $ 23 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
7.4 M | $ 0.75 | 2.35 % | $ 3.22 M | ||
|
TherapeuticsMD
TXMD
|
4.78 M | $ 2.28 | 3.64 % | $ 26.4 M |